LKT Labs

Biochemicals for Life Science Research

Medroxyprogesterone 17-Acetate

Medroxyprogesterone 17-Acetate

Product ID M1613
Cas No. 71-58-9
Purity ≥99%
Product Unit SizeCostQuantityStock
500 mg $77.80 In stock
1 g $129.80 In stock
5 g $498.50 In stock
Bulk Quote

Quicklinks

Description

Medroxyprogesterone 17-acetate (MPA) is a synthetic steroid that activates progesterone, androgen, and glucocorticoid receptors. MPA exhibits contraceptive and anticancer activities and is also used in hormone replacement therapy, endometriosis, and dysmenorrhea. MPA decreases levels of adrenocorticotropic hormone (ACTH), cortisol, and other hormones; it also inhibits 3α-hydroxysteroid dehydrogenase. This compound is used clinically to treat breast cancer and inhibits the proliferation and growth of breast cancer cells and tumors in various models.

Product Info

Cas No.

71-58-9
Purity

≥99%
Formula

C24H34O4
Formula Wt.

386.52
Chemical Name

17-α-Acetoxy-6α-methylprogesterone
IUPAC Name

[(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9, 11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
Synonym

MAP, Clinovir, Depo-Provera, Farlutal, Nidaxin, Oragest, Prodasone, Provera, Veramix
Melting Point

207-209°C
Solubility

Soluble in chloroform or acetone.

Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

M1613 MSDS PDF
Info Sheet

M1613 Info Sheet PDF

References

Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2008 Sep-Oct;61(1-2):171-80. PMID: 19434889.

Meyer L, Venard C, Schaeffer V, et al. The biological activity of 3alpha-hydroxysteroid oxido-reductase in the spinal cord regulates thermal and mechanical pain thresholds after sciatic nerve injury. Neurobiol Dis. 2008 Apr;30(1):30-41. PMID: 18291663.

Poulin R, Baker D, Poirier D, et al. Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Breast Cancer Res Treat. 1989 Mar;13(2):161-72. PMID: 2525057.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • A9708

    AZD-1208

    Pim-1 inhibitor.

    ≥98%
  • V7200

    VS-5584

    PI3K inhibitor.

    ≥98%
  • W0273

    R-(+)-Warfarin >99%ee

    Coumarin; VKORC1 inhibitor.

    ≥99%
  • H9763

    Hypoxanthine

    Endogenous purine derivative of xanthine.

    ≥98%
  • B1878

    Betamethasone 21-Phosphate Sodium

    Steroid; glucocorticoid agonist.

    ≥98%
  • T1754

    Tenatoprazole

    H+/K+ ATPase inhibitor.

    ≥98%
  • L1878

    Letrozole

    Aromatase inhibitor.

    ≥98%
  • G4799

    Glycitin

    Glycosylated isoflavone found in soy; TAS2R ago...

    ≥98%
  • C3477

    Citalopram Hydrobromide

    SERT inhibitor.

    ≥98%
  • N859610

    NVP-HDM201

    HDM2 inhibitor

    ≥99%
  • A7333

    Asiaticoside

    Triterpene found in Centella, prevents melanoge...

    ≥90%
  • A4930

    7-Aminoactinomycin D

    Actinomycin derivative used to study apoptosis ...

    ≥98%
  • V3455

    Vinpocetine

    Targets nuclear factor kappa B activation.

    ≥98%
  • K6276

    (E)-KPT-330

    CRM1-selective inhibitor of nuclear export.

    ≥99%
  • J0274

    Jasplakinolide

    Marine toxin; actin polymerization inducer.

    ≥98%
  • A1368

    Adrenomedullin (1-52), human

    Endogenous peptide hormone, involved in cell gr...

    ≥95%
  • T1010

    7-Acetyl Paclitaxel

    Synthesis impurity

    ≥98%
  • D019601

    Dapagliflozin

    SGLT2 inhibitor

    ≥98%
  • F5870

    N-formyl-Met-Leu-Phe

    Peptide, involved in neutrophil activation; FPR...

    ≥95%
  • F4679

    Flubendazole

    Benzimidazole; microtubule polymerization inhib...

    ≥98%